Charles River Laboratories International, Inc. (CRL) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Charles River Laboratories International’s revenue went from $1.7B in fiscal 2016 to $4.0B in fiscal 2025, growth of about 10.2% a year.
Net income in fiscal 2025 was -$144M, a net margin of -3.6%; the best year in this period was 2022 with $486M.
Over the twelve months to September 26, 2026, revenue was $4.0B and net income $40M.
Free cash flow was $518M in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count rose 3% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.0B | $4.0B | $4.0B | $4.1B | $4.0B | $3.5B | $2.9B | $2.6B | $2.3B | $1.9B | $1.7B |
| Gross profit | — | — | — | — | — | — | — | — | — | $1.6B | $1.4B |
| Operating income | $159M | $25M | $227M | $617M | $651M | $590M | $433M | $351M | $331M | $288M | $238M |
| Net income | $40M | -$144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M |
| EPS (diluted) | $0.92 | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | −0.9% | −1.9% | +3.9% | +12.3% | +21.1% | +11.6% | +15.7% | +22.0% | +10.5% | +23.3% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $622M | $738M | $735M | $684M | $620M | $761M | $547M | $481M | $441M | $318M | $317M |
| Capital spending | -$223M | -$219M | -$233M | -$319M | -$325M | -$229M | -$167M | -$141M | -$140M | -$82M | -$55M |
| Free cash flow | $400M | $518M | $502M | $365M | $295M | $532M | $380M | $340M | $301M | $236M | $262M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $324M | $361M | $119M | $24M | $39M | $41M | $24M | $18M | $14M | $107M | $12M |
| Stock-based pay | $81M | $71M | $70M | $72M | $74M | $71M | $56M | $57M | $47M | $44M | $44M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $214M | $195M | $277M | $234M | $242M | $229M | $239M | $196M | $192M | $121M |
| Debt | — | $2.6B | $2.8B | $3.1B | $3.1B | $2.9B | $2.2B | $2.0B | $1.8B | $1.1B | $1.2B |
| Equity | — | $3.2B | $3.5B | $3.6B | $3.0B | $2.5B | $2.1B | $1.6B | $1.3B | $1.0B | $837M |
| Total assets | — | $7.1B | $7.5B | $8.2B | $7.6B | $7.0B | $5.5B | $4.7B | $3.9B | $2.9B | $2.7B |
| Shares (diluted) | 49M | 50M | 52M | 51M | 51M | 51M | 51M | 50M | 49M | 49M | 48M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | 84.4% | 83.5% |
| Operating margin | 4.0% | 0.6% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% |
| Net margin | 1.0% | -3.6% | 0.5% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% |
| FCF margin | 10.0% | 12.9% | 12.4% | 8.8% | 7.4% | 15.0% | 13.0% | 13.0% | 13.3% | 12.7% | 15.6% |
| ROIC | — | 0.3% | 2.9% | 7.6% | 8.4% | 8.9% | 8.3% | 8.0% | 8.7% | 10.5% | 8.1% |
| ROE | — | -4.6% | 0.6% | 13.2% | 16.3% | 15.4% | 17.2% | 15.4% | 17.2% | 11.8% | 18.5% |
Frequently asked questions
What is Charles River Laboratories International’s annual revenue?
$4.0B in fiscal 2025 and $4.0B over the twelve months to September 26, 2026.
How much profit does Charles River Laboratories International make?
Net income was -$144M in fiscal 2025 (net margin -3.6%).
Is Charles River Laboratories International’s revenue growing?
No: revenue fell 0.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.